# RSVpreF (bivalent RSV prefusion F protein vaccine)

Drug · id `maternal:rsvpref-vaccine` · Maternal & Newborn Atlas · release `fc5a600ec7387e71` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: RSVpreF

Browse, life stage: Pregnancy; Infant follow-up  
Browse, care area: The baby's first year  

## In plain language

The vaccine substance in Abrysvo: stabilised RSV prefusion F proteins of the A and B types in one vaccine. It is the substance tested in the MATISSE trial.

## Technical summary

A fixed combination of the RSV A and B stabilised prefusion F protein drug substances (US approval letter; MATISSE abstract: a bivalent RSV prefusion F protein-based vaccine). RxNorm precise-ingredient concepts for the A and B proteins are RXCUI 2642138 and 2642139, recorded as broad codes because each is one part of the combination; they were looked up in RxNav, not quoted. The product is Abrysvo.

## Connected pages

- Filed under this front: Medicines and vaccines (`maternal:front-medicines-and-vaccines`)
- Contained in: Abrysvo (RSV vaccine, Pfizer) (`maternal:abrysvo`)
- Investigated in: MATISSE trial (maternal RSV vaccine, infant outcomes) (`maternal:matisse-trial`)

## Provenance

Content hash: 08ba54c44a90604df24d75368320f29d4d7079eb6a197d25a4df200d2a61b14b
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-15